Linagliptin: from bench to bedside

References

• Ohlsson L Alsalim W Carr RD Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects Diabetes Obes Metab 2013 15 6 531 537 23331498
   PubMed Web of Science ®Google Scholar
• Tradjenta (linagliptin) [prescribing information] Ingelheim am Rhein, Germany Boehringer Ingelheim Pharmaceuticals Inc. 2013 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf Accessed July 23, 2013
   Google Scholar
• Eckhardt M Langkopf E Mark M 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J Med Chem 2007 50 26 6450 6453 18052023
   PubMed Web of Science ®Google Scholar
• Januvia (sitagliptin) [prescribing information] Whitehouse Station, NJ Merck and Co, Inc 2013 Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf Accessed July 23, 2013
   Google Scholar
• Koliaki C Doupis J Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus Diabetes Ther 2011 2 2 101 121 22127804
   PubMedGoogle Scholar
• Doupis J Veves A DPP4 inhibitors: a new approach in diabetes treatment Adv Ther 2008 25 7 627 643 18641927
   PubMed Web of Science ®Google Scholar
• Onglyza (saxagliptin) [prescribing information] New York, NY Bristol-Myers Squibb 2013 Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdf Accessed June 14, 2013
   Google Scholar
• Agrawal R Jain P Dikshit SN Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor Curr Drug Targets 2012 13 7 970 983 22420306
   PubMed Web of Science ®Google Scholar
• Fuchs H Tillement JP Urien S Greischel A Roth W Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans J Pharm Pharmacol 2009 61 1 55 62 19126297
   PubMed Web of Science ®Google Scholar
• Heise T Graefe-Mody EU Hüttner S Ring A Trommeshauser D Dugi KA Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 2009 11 8 786 794 19476474
   PubMed Web of Science ®Google Scholar
• Eckhardt M Hauel N Himmelsbach F 3,5-Dihydro-imidazo[4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitors Bioorg Med Chem Lett 2008 18 11 3158 3162 18485703
   PubMed Web of Science ®Google Scholar
• Fuchs H Runge F Held HD Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux Eur J Pharm Sci 2012 45 5 533 538 22198311
   PubMed Web of Science ®Google Scholar
• Thomas L Eckhardt M Langkopf E Tadayyon M Himmelsbach F Mark M (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J Pharmacol Exp Ther 2008 325 1 175 182 18223196
   PubMed Web of Science ®Google Scholar
• Thomas L Tadayyon M Mark M Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models J Pharmacol Exp Ther 2009 328 2 556 563 18971371
   PubMed Web of Science ®Google Scholar
• Retlich S Duval V Ring A Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg–10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects Clin Pharmacokinet 2010 49 12 829 840 21053992
   PubMed Web of Science ®Google Scholar
• Golightly LK Drayna CC McDermott MT Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors Clin Pharmacokinet 2012 51 8 501 514 22686547
   PubMed Web of Science ®Google Scholar
• Blech S Ludwig-Schwellinger E Gräfe-Mody EU Withopf B Wagner K The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab Dispos 2010 38 4 667 678 20086031
   PubMed Web of Science ®Google Scholar
• Christopher R Covington P Davenport M Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects Clin Ther 2008 30 3 513 527 18405789
   PubMed Web of Science ®Google Scholar
• He H Tran P Yin H Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Drug Metab. Dispos 2009 37 3 536 544 19074975
   PubMed Web of Science ®Google Scholar
• Vincent SH Reed JR Bergman AJ Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans Drug Metab Dispos 2007 35 4 533 538 17220239
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Rose P Retlich S Pharmacokinetics of linagliptin in subjects with hepatic impairment Br J Clin Pharmacol 2012 74 1 75 85 22242621
   PubMed Web of Science ®Google Scholar
• Rauch T Graefe-Mody U Deacon CF Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus Diabetes Ther 2012 3 1 10 22986920
   PubMedGoogle Scholar
• Shah P Ardestani A Dharmadhikari G The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization J Clin Endocrinol Metab 2013 98 7 E1163 E1172 23633194
   PubMed Web of Science ®Google Scholar
• Vickers SP Cheetham SC Birmingham GD Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals Clin Lab 2012 58 7–8 787 799 22997980
   PubMed Web of Science ®Google Scholar
• Darsalia V Ortsäter H Olverling A The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride Diabetes 2013 62 4 1289 1296 23209191
   PubMed Web of Science ®Google Scholar
• Schurmann C Linke A Engelmann-Pilger K The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice J Pharmacol Exp Ther 2012 342 1 71 80 22493041
   PubMed Web of Science ®Google Scholar
• Goren I Müller E Pfeilschifter J Frank S Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha Am J Pathol 2006 168 3 765 777 16507892
   PubMed Web of Science ®Google Scholar
• Eming SA Krieg T Davidson JM Inflammation in wound repair: molecular and cellular mechanisms J Invest Dermatol 2007 127 3 514 525 17299434
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Center For Drug Evaluation and Research. Application Number: 201280Orig1s000. Summary Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000SumR.pdf Accessed April 18, 2013
   Google Scholar
• Barnett AH Patel S Harper R Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension Diabetes Obes Metab 2012 14 12 1145 1154 22974280
   PubMed Web of Science ®Google Scholar
• Del Prato S Linagliptin for the treatment of type 2 diabetes Expert Opin Pharmacother 2011 12 17 2759 2762 21883034
   PubMed Web of Science ®Google Scholar
• Del Prato S Barnett AH Huisman H Neubacher D Woerle HJ Dugi KA Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes Obes Metab 2011 13 3 258 267 21205122
   PubMed Web of Science ®Google Scholar
• Forst T Uhlig-Laske B Ring A Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes Diabet Med 2010 27 12 1409 1419 21059094
   PubMed Web of Science ®Google Scholar
• Taskinen MR Rosenstock J Tamminen I Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 1 65 74 21114605
   PubMed Web of Science ®Google Scholar
• Owens DR Swallow R Dugi KA Woerle HJ Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study Diabet Med 2011 28 11 1352 1361 21781152
   PubMed Web of Science ®Google Scholar
• Haak T Meinicke T Jones R Weber S von Eynatten M Woerle HJ Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2012 14 6 565 574 22356132
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration CDER Drug and Biologic Calendar Year Approvals as of December 31, 2012 Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ucm342732.pdf Accessed March 18, 2014
   Google Scholar
• Gomis R Espadero RM Jones R Woerle HJ Dugi KA Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 7 653 661 21410628
   PubMed Web of Science ®Google Scholar
• Lewin AJ Arvay L Liu D Patel S von Eynatten M Woerle HJ Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial Clin Ther 2012 34 9 1909 1919. e15 22939034
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H Rosenstock J Durán-Garcia S Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes. A ≥52-week randomized, double-blind study Diabetes Care 2013 36 12 3875 3881 24062327
   PubMed Web of Science ®Google Scholar
• Kawamori R Inagaki N Araki E Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study Diabetes Obes Metab 2012 14 4 348 357 22145698
   PubMed Web of Science ®Google Scholar
• Hüttner S Graefe-Mody EU Withopf B Ring A Dugi KA Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers J Clin Pharmacol 2008 48 10 1171 1178 18812608
   PubMed Web of Science ®Google Scholar
• Schernthaner G Barnett AH Emser A Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus Diabetes Obes Metab 2012 14 5 470 478 22268497
   PubMed Web of Science ®Google Scholar
• Gallwitz B Rosenstock J Rauch T 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 2012 380 9840 475 483 22748821
   PubMed Web of Science ®Google Scholar
• Gallwitz B Rosenstock J Emser A von Eynatten M Woerle HJ Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c <7% with no hypoglycaemia and no weight gain over 2 years Int J Clin Pract 2013 67 4 317 321 23521323
   PubMed Web of Science ®Google Scholar
• Gomis R Owens DR Taskinen MR Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension Int J Clin Pract 2012 66 8 731 740 22691164
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Klein T Niessen HG Ittrich C Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine Diabetes Obes Metab 2012 14 11 1050 1053 22651241
   PubMed Web of Science ®Google Scholar
• Kern M Klöting N Niessen HG Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity PLoS One 2012 7 6 e38744 22761701
   PubMed Web of Science ®Google Scholar
• Monami M Iacomelli I Marchionni N Mannucci E Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 2010 20 4 224 235 19515542
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
   PubMed Web of Science ®Google Scholar
• Chaykovska L von Websky K Rahnenfuhrer J Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy PLoS One 2011 6 11 e27861 22125632
   PubMed Web of Science ®Google Scholar
• Nicholas SB Liu J Kim J Critical role for osteopontin in diabetic nephropathy Kidney Int 2010 77 7 588 600 20130530
   PubMed Web of Science ®Google Scholar
• Alter ML Ott IM von Websky K DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy Kidney Blood Press Res 2012 36 1 119 130 23171828
   PubMed Web of Science ®Google Scholar
• Hocher B Reichetzeder C Alter ML Renal and cardiac effects of DPP4 inhibitors – from preclinical development to clinical research Kidney Blood Press Res 2012 36 1 65 84 22947920
   PubMed Web of Science ®Google Scholar
• Marney A Kunchakarra S Byrne L Brown NJ Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 2010 56 4 728 733 20679179
   PubMed Web of Science ®Google Scholar
• Chaykovska L Alter ML von Websky K Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension J Hypertens 2013 31 11 2290 2298 discussion 2299 24077249
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Friedrich C Port A Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*) Diabetes Obes Metab 2011 13 10 939 946 21672124
   PubMed Web of Science ®Google Scholar
• McGill JB Sloan L Newman J Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study Diabetes Care 2013 36 2 237 244 23033241
   PubMed Web of Science ®Google Scholar
• Laakso M Rosentstock J Groop PH Linagliptin vs placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment Diabetes 2013 62 Suppl 1 A281 A282 Abstract
   Google Scholar
• Groop P-H Cooper ME Perkovic V Emser H Woerle HJ von Eynatten M Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction Diabetes Care 2013 36 11 3460 3468 24026560
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim MARLINA – T2D^™: efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease With LINAgliptin Available from: http://clinicaltrials.gov/ct2/show/NCT01792518?term=MARLINA&rank=1. NLM identifier: NCT01792518 Accessed June 19, 2013
   Google Scholar
• Lan CC Wu CS Huang SM Wu IH Chen GS High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights on impaired diabetic wound healing Diabetes 2013 62 7 2530 2538 23423570
   PubMed Web of Science ®Google Scholar
• Blakytny R Jude E The molecular biology of chronic wounds and delayed healing in diabetes Diabet Med 2006 23 6 594 608 16759300
   PubMed Web of Science ®Google Scholar
• Marfella R Sasso FC Rizzo MR Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes Exp Diabetes Res 2012 2012 892706 23197976
   PubMedGoogle Scholar
• Ban K Hui S Drucker DJ Husain M Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies J Am Soc Hypertens 2009 3 4 245 259 20409967
   PubMed Web of Science ®Google Scholar
• Hocher B Sharkovska Y Mark M Klein T Pfab T The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats Int J Cardiol 2013 167 1 87 93 22217485
   PubMed Web of Science ®Google Scholar
• Takasawa W Ohnuma K Hatano R Endo Y Dang NH Morimoto C Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines Biochem Biophys Res Commun 2010 401 1 7 12 20828536
   PubMed Web of Science ®Google Scholar
• Ferreira L Teixeira-de-Lemos E Pinto F Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediators Inflamm 2010 2010 592760 20652060
   PubMed Web of Science ®Google Scholar
• Kröller-Schön S Knorr M Hausding M Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition Cardiovasc Res 2012 96 1 140 149 22843705
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Guidance for Industry: Diabetes Mellitus--Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed May 30, 2013
   Google Scholar
• Johansen OE Neubacher D von Eynatten M Patel S Woerle HJ Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 2012 11 3 22234149
   PubMed Web of Science ®Google Scholar
• Johansen OE Neubacher D Seck T Patel S Woerle HJ Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes (T2D): a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies Diabetes 2013 62 Suppl 1 A96 Abstract
   Google Scholar
• Boehringer Ingelheim CAROLINA^®: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes Available from: http://clinicaltrials.gov/ct2/show/NCT01243424?term=linagliptin&rank=12. NLM identifier: NCT01243424 Accessed June 7, 2013
   Google Scholar
• Rosenstock J Marx N Kahn SE Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 2013 10 4 289 301 23449634
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim CARMELINA^®: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk Available from: http://clinicaltrials.gov/ct2/show/NCT01897532?term=CARMELINA&rank=1. NLM identifier: NCT01897532 Accessed August 21, 2013
   Google Scholar
• Huypens P Ling Z Pipeleers D Schuit F Glucagon receptors on human islet cells contribute to glucose competence of insulin release Diabetologia 2000 43 8 1012 1019 10990079
   PubMed Web of Science ®Google Scholar
• Moens K Heimberg H Flamez D Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells Diabetes 1996 45 2 257 261 8549871
   PubMed Web of Science ®Google Scholar
• Schuit FC Huypens P Heimberg H Pipeleers DG Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus Diabetes 2001 50 1 1 11 11147773
   PubMed Web of Science ®Google Scholar
• Drucker DJ Philippe J Mojsov S Chick WL Habener JF Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line Proc Natl Acad Sci U S A 1987 84 10 3434 3438 3033647
   PubMed Web of Science ®Google Scholar
• Scheen AJ DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials Diabetes Metab 2012 38 2 89 101 22197148
   PubMed Web of Science ®Google Scholar
• Ahrén B Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? Curr Diab Rep 2011 11 2 83 90 21243448
   PubMed Web of Science ®Google Scholar
• Gallwitz B Häring HU Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas Diabetes Obes Metab 2010 12 1 1 11 19788431
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• United States Renal Data System 2013 USRDS Annual Data Report: Chronic Kidney Disease in the General Population Available from: http://www.usrds.org/2013/pdf/v1_ch1_13.pdf Accessed March 19, 2014
   Google Scholar
• United States Renal Data System USRDS 2009 Annual Data Report Available from: http://www.usrds.org/2009/pdf/V2_02_INC_PREV_09.pdf Accessed June 7, 2013
   Google Scholar
• Meyers JL Candrilli SD Kovacs B Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment Postgrad Med 2011 123 3 133 143 21566423
   PubMed Web of Science ®Google Scholar
• Kirkman M Briscoe VJ Clark N Diabetes in older adults: a consensus report J Am Geriatr Soc 2012 60 12 2342 2356 23106132
   PubMed Web of Science ®Google Scholar
• Barnett AH Huisman H Jones R von Eynatten M Patel S Woerle HJ Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial Lancet 2013 383 9902 1413 1423 23948125
   PubMed Web of Science ®Google Scholar
• Cuthbertson DJ Irwin A Gardner CJ Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists PLoS One 2012 7 12 e50117 23236362
   PubMed Web of Science ®Google Scholar
• Forst T Uhlig-Laske B Ring A Ritzhaupt A Graefe-Mody U Dugi KA The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus Diabetes Obes Metab 2011 13 6 542 550 21352464
   PubMed Web of Science ®Google Scholar
• Itou M Kawaguchi T Taniguchi E Oriishi T Sata M Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: a case report Case Rep Gastroenterol 2012 6 2 538 544 22949894
   PubMedGoogle Scholar
• Ross SA Rafeiro E Meinicke T Toorawa R Weber-Born S Woerle HJ Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial Curr Med Res Opin 2012 28 9 1465 1474 22816729
   PubMed Web of Science ®Google Scholar
• Sathyanarayana P Jogi M Muthupillai R Krishnamurthy R Samson SL Bajaj M Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes Obesity (Silver Spring) 2011 19 12 2310 2315 21660077
   PubMed Web of Science ®Google Scholar